TB Alliance fails to get patent for six-month treatment regimen

TL;DR

• The Indian Patent Office on Tuesday rejected a patent application for BPaL, a combination of three medicines that has cut treatment for drug-resistant tuberculosis (TB) to six months, according to a joint statement by the groups that opposed it